Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy gene therapy, while Verizon tops earnings expectation and raises 2025 ...

Block Inc. shares jumped 9% in premarket following news late Friday that the parent company of Square [will join the S&P 500 this week]( ...

U.S. stock futures rise as investors brace for a high-stakes week packed with Tesla and Alphabet earnings and growing anxiety ...

Investing.com - 美国银行证券公司维持对沙雷普塔治疗公司 ( Sarepta Therapeutics) (NASDAQ: SRPT )的"中性"评级和20.00美元的目标价，此前该公司宣布FDA提出安全要求。过去一年，该股已下跌近90%，尤其是在最近安全担忧出现后跌幅加剧。根据 InvestingPro 数据显示，该公司的RSI指标表明该股目前处于超卖区域。